×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Sarcoma

Staff Writer
A recent trial presented an unexpected survival benefit for patients with high-risk soft tissue sarcoma who were on anthracycline-based neoadjuvant chemotherapy.
Laura Panjwani
Immunotherapy may not end up being as successful in treating sarcoma as it is in other types of cancer, says Katherine Thornton M.D. 
Arlene Weintraub


The 50 cancers under the umbrella of soft tissue sarcoma are marked by genetic chaos, and a growing understanding of these mutations may lead to new treatments. 

Laura Panjwani
Keytruda is showing benefit to some patients with sarcoma, according to interim results from a phase 2 trial. 
Gina Columbus
CURE spoke with Noah Federman about the prevalence and treatment of sarcomas in younger patients. 
Jason M. Broderick
The FDA granted olaratumab a priority review for some people with advanced soft tissue sarcoma (STS). 
Rebekah Harrison
When it comes to fighting sarcoma, the Sarcoma Foundation of America does not stop at fundraising.
Jason M. Broderick
The breakthrough designation will expedite the development and review of this novel T-cell therapy in synovial sarcoma.
Silas Inman
The approval of Halaven was based on an improvement in overall survival (OS) in a phase 3 study.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other